Merck will buy ArQule — which develops pills designed to treat multiple types of cancer — for $2.7 billion, a 107 percent premium above the stock’s closing price Dec. 6.
Sanofi will buy Synthorx — which develops treatments for cancer and autoimmune diseases — for $2.5 billion, a 172 percent premium above the stock’s closing price Dec. 6.
The acquisitions follow a trend of large drugmakers buying smaller companies developing cancer treatments. In the last year, Pfizer has purchased Array Biopharma — which developed skin cancer treatments as well as other experimental cancer drugs — for $11.4 billion, and Eli Lilly has bought Loxo Oncology — which specialized in cancer treatments — for $8 billion.
Read the full article here.
More articles on pharmacy:
UnitedHealth to acquire struggling specialty pharmacy
Pharmaceutical layoffs up nearly 6% from last year
Larger chunk of hospital drug spending going toward cancer treatments, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
